Abstract
Steroid hormone receptors are critical for the growth and development of breast tissue as well as of breast cancer. The importance of the role estrogens in breast cancer has been delineated for more than 100 years. The analysis of its expression has been used not only to classify breast cancers but also for treating patients. The expression of ER and PR in tumors is associated with better prognosis and sensitivity to endocrine therapy. In this chapter we discuss the role of these receptors in addition to androgen receptor (AR) in breast cancer. A brief overview of the structure and function of these receptors and methods to detect their presence in breast cancer is presented. This includes criteria for scoring positivity and national and international guidelines associated with the scoring. Lastly, data regarding the use of expression of AR as therapeutic target, particularly in triple negative cancers, is presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 30(12):1268–1273. doi:10.1200/JCO.2010.34.0141
Andersen J, Orntoft T, Poulsen HS (1986) Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies. Br J Cancer 53(5):691–694
Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI (1994) Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 74(1):74–77
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038. doi:10.1056/NEJMoa1315815
Arnedos M, Nerurkar A, Osin P, A’Hern R, Smith IE, Dowsett M (2009) Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20(12):1948–1952. doi:10.1093/annonc/mdp234
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973–1979. doi:10.1200/JCO.2003.09.099
Barentsz MW, Wessels H, van Diest PJ, Pijnappel RM, van der Pol CC, Witkamp AJ, van den Bosch MA, Verkooijen HM (2014) Same-day diagnosis based on histology for women suspected of breast cancer: high diagnostic accuracy and favorable impact on the patient. PLoS ONE 9(7):e103105. doi:10.1371/journal.pone.0103105
Barnes DM, Fentiman IS, Millis RR, Rubens RD (1989) Who needs steroid receptor assays? Lancet 1(8647):1126–1127
Barone I, Brusco L, Fuqua SA (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16(10):2702–2708. doi:10.1158/1078-0432.CCR-09-1753
Beatson GW (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 148:104–107
Bolton KL, Garcia-Closas M, Pfeiffer RM, Duggan MA, Howat WJ, Hewitt SM, Yang XR, Cornelison R, Anzick SL, Meltzer P, Davis S, Lenz P, Figueroa JD, Pharoah PD, Sherman ME (2010) Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol Biomarkers Prev 19(4):992–999. doi:10.1158/1055-9965.EPI-09-1023
Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ (2010) The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 21(1):40–47. doi:10.1093/annonc/mdp273
Burge CN, Chang HR, Apple SK (2006) Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 15(2):167–172. doi:10.1016/j.breast.2005.06.004
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gomez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK (2014) Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 16(1):R7. doi:10.1186/bcr3599
Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 24(7):924–931. doi:10.1038/modpathol.2011.54
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R, Adjuvant Tamoxifen: Longer Against Shorter Collaborative G (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381 (9869):805–816. doi:10.1016/S0140-6736(12)61963-1
Dekker TJ, ter Borg S, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CH, Sleddens HF, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ (2015) Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. Breast Cancer Res Treat 152(2):247–252. doi:10.1007/s10549-015-3444-x
Dowsett M (2006) Estrogen receptor: methodology matters. J Clin Oncol 24(36):5626–5628. doi:10.1200/JCO.2006.08.3485
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A, Cuzick J (2015) Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer. Clin Cancer Res 21(12):2763–2770. doi:10.1158/1078-0432.CCR-14-2842
Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A (2010) Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 21(6):1243–1245. doi:10.1093/annonc/mdp450
Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
Feherty P, Farrer-Brown G, Kellie AE (1971) Oestradiol receptors in carcinoma and benign disease of the breast: an in vitro assay. Br J Cancer 25(4):697–710
Ferguson AT, Lapidus RG, Baylin SB, Davidson NE (1995) Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55(11):2279–2283
Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN (2005) Adjuvant systemic therapy for male breast carcinoma. Cancer 104(11):2359–2364. doi:10.1002/cncr.21526
Gray RG (2013) aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. In: Abstract ASCO annual meeting 2013. J Clin Oncol (suppl; abstr 5)
Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A, Ferno M (2007) Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13(7):1987–1994. doi:10.1158/1078-0432.CCR-06-1823
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/JCO.2009.25.6529
Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481
Heinlein CA, Chang C (2002) The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16(10):2181–2187. doi:10.1210/me.2002-0070
Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EG, van der Wall E, van Diest PJ (2010) Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12(5):R75. doi:10.1186/bcr2645
Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van Gils CH, van der Wall E, van Diest PJ (2012) Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer 118(20):4929–4935. doi:10.1002/cncr.27518
Holst F, Moelans CB, Filipits M, Singer CF, Simon R, van Diest PJ (2012) On the evidence for ESR1 amplification in breast cancer. Nat Rev Cancer 12(2):149. doi:10.1038/nrc3093-c3
Hu DG, Hickey TE, Irvine C, Wijayakumara DD, Lu L, Tilley WD, Selth LA, Mackenzie PI (2014) Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. Horm Cancer 5(2):61–71. doi:10.1007/s12672-014-0171-4
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L (2012) Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1 % to 10 % ER-positive by immunohistochemistry. J Clin Oncol 30(7):729–734. doi:10.1200/JCO.2011.36.2574
Jensen EV (1981) Hormone dependency of breast cancer. Cancer 47(10):2319–2326
Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R (2015) ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 12(10):573–583. doi:10.1038/nrclinonc.2015.117
Jozwik KM, Carroll JS (2012) Pioneer factors in hormone-dependent cancers. Nat Rev Cancer 12(6):381–385. doi:10.1038/nrc3263
Kalkman S, Barentsz MW, Witkamp AJ, van der Wall E, Verkooijen HM, van Diest PJ (2014) Brief fixation does not affect assessment of hormone receptor expression in invasive breast carcinoma biopsies: paving the road for same-day tissue diagnostics. Am J Surg Pathol 38(8):1071–1078. doi:10.1097/PAS.0000000000000207
King WJ, DeSombre ER, Jensen EV, Greene GL (1985) Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res 45(1):293–304
Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ (2012) Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 25(3):398–404. doi:10.1038/modpathol.2011.174
Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2(5):805–810
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. doi:10.1172/JCI45014
Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046–1052. doi:10.1038/sj.bjc.6602787
Lloyd MC, Allam-Nandyala P, Purohit CN, Burke N, Coppola D, Bui MM (2010) Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: how reliable is it? J Pathol Inform 1:29. doi:10.4103/2153-3539.74186
Marino M, Galluzzo P, Ascenzi P (2006) Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 7(8):497–508
Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I (2013) D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 73(23):6856–6864. doi:10.1158/0008-5472.CAN-13-1197
Moelans CB, Holst F, Hellwinkel O, Simon R, van Diest PJ (2013) ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous. PLoS ONE 8(12):e84189. doi:10.1371/journal.pone.0084189
Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M (2015) Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol 26(2):307–313. doi:10.1093/annonc/mdu528
Motamedolshariati M, Memar B, Aliakbaian M, Shakeri MT, Samadi M, Jangjoo A (2014) Accuracy of prognostic and predictive markers in core needle breast biopsies compared with excisional specimens. Breast Care (Basel) 9(2):107–110. doi:10.1159/000360787
Muresan Z, Dutu R, Voiculetz N (1986) Relationships of steroid hormone receptors, age and histological characteristics in human breast cancer. Neoplasma 33(3):371–377
Nakshatri H, Badve S (2007) FOXA1 as a therapeutic target for breast cancer. Expert Opin Ther Targets 11(4):507–514. doi:10.1517/14728222.11.4.507
Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Kitamura SS, Ikeda H, Kawashima H, Dobashi Y (2012) Gene amplification of ESR1 in breast cancers–fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol 227(1):8–16. doi:10.1002/path.3974
Postma EL, Verkooijen HM, van Diest PJ, Willems SM, van den Bosch MA, van Hillegersberg R (2013) Discrepancy between routine and expert pathologists’ assessment of non-palpable breast cancer and its impact on locoregional and systemic treatment. Eur J Pharmacol 717(1–3):31–35. doi:10.1016/j.ejphar.2012.12.033
Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver MJ (2009) Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15(22):7003–7011. doi:10.1158/1078-0432.CCR-09-0449
Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, Parl FF (1995) Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 87(6):446–451
Safarpour D, Pakneshan S, Tavassoli FA (2014) Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res 4(4):353–368
Sefrioui D, Perdrix A, Sarafan-Vasseur N, Dolfus C, Dujon A, Picquenot JM, Delacour J, Cornic M, Bohers E, Leheurteur M, Rigal O, Tennevet I, Thery JC, Alexandru C, Guillemet C, Moldovan C, Veyret C, Frebourg T, Di Fiore F, Clatot F (2015) Short report: monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer 137(10):2513–2519. doi:10.1002/ijc.29612
Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ, O’Malley BW (1997) Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 52:141–164; discussion 164–145
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874. doi:10.1073/pnas.191367098
Tamaki K, Sasano H, Ishida T, Miyashita M, Takeda M, Amari M, Tamaki N, Ohuchi N (2010) Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci 101(9):2074–2079. doi:10.1111/j.1349-7006.2010.01630.x
Taylor SE, Martin-Hirsch PL, Martin FL (2010) Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett 288(2):133–148. doi:10.1016/j.canlet.2009.06.017
Thomas C, Gustafsson J-Å (2011) Not enough evidence to include ESR1 amplification. Nat Rev Cancer 11(11):823
Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12(4):R56. doi:10.1186/bcr2615
Veta M, Pluim JP, van Diest PJ, Viergever MA (2014) Breast cancer histopathology image analysis: a review. IEEE Trans Biomed Eng 61(5):1400–1411. doi:10.1109/TBME.2014.2303852
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thurlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25(25):3846–3852. doi:10.1200/JCO.2007.11.9453
Walters KA, Simanainen U, Handelsman DJ (2010) Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 16(5):543–558. doi:10.1093/humupd/dmq003
Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL (2014) ERbeta splice variant expression in four large cohorts of human breast cancer patient tumors. Breast Cancer Res Treat 146(3):657–667. doi:10.1007/s10549-014-3050-3
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK (2014) Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 25(5):1004–1011. doi:10.1093/annonc/mdu053
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Suijkerbuijk, K.P.M., van der Wall, E., van Diest, P.J. (2016). Hormone Receptors in Breast Cancer. In: Badve, S., Gökmen-Polar, Y. (eds) Molecular Pathology of Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-41761-5_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-41761-5_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41759-2
Online ISBN: 978-3-319-41761-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)